These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 9777314

  • 1. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Wiseman LR, Spencer CM.
    Drugs; 1998 Sep; 56(3):385-403. PubMed ID: 9777314
    [Abstract] [Full Text] [Related]

  • 2. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
    Cvetković RS, Scott LJ.
    Drugs; 2005 Sep; 65(7):1005-24. PubMed ID: 15892593
    [Abstract] [Full Text] [Related]

  • 3. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M, Michelotti A, Del Mastro L, Gallo L, Carnino F, Garrone O, Tibaldi C, Molea N, Bellina RC, Pronzato P, Cyrus P, Vinke J, Testore F, Guelfi M, Lionetto R, Bruzzi P, Conte PF, Rosso R.
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cardioprotective effect of dexrazoxane in patients with breast cancer treated with anthracyclines in adjuvant setting: a 10-year single institution experience.
    Testore F, Milanese S, Ceste M, de Conciliis E, Parello G, Lanfranco C, Manfredi R, Ferrero G, Simoni C, Miglietta L, Ferro S, Giaretto L, Bosso G.
    Am J Cardiovasc Drugs; 2008 Dec; 8(4):257-63. PubMed ID: 18690759
    [Abstract] [Full Text] [Related]

  • 8. [Dexrazoxane. Current status and prospectives of cardiotoxicity of chemotherapy].
    Lopez M.
    Clin Ter; 1999 Dec; 150(1):37-49. PubMed ID: 10367544
    [Abstract] [Full Text] [Related]

  • 9. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Swain SM.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):43-7. PubMed ID: 9768823
    [Abstract] [Full Text] [Related]

  • 10. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
    Bryant J, Picot J, Levitt G, Sullivan I, Baxter L, Clegg A.
    Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
    [Abstract] [Full Text] [Related]

  • 11. Clinical status and optimal use of the cardioprotectant, dexrazoxane.
    Blum RH.
    Oncology (Williston Park); 1997 Nov; 11(11):1669-77; discussion 1677-8, 1681. PubMed ID: 9394365
    [No Abstract] [Full Text] [Related]

  • 12. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
    Tyson AM, Gay WE.
    Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
    [Abstract] [Full Text] [Related]

  • 13. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
    Chow WA, Synold TW, Tetef ML, Longmate J, Frankel P, Lawrence J, Al-Khadimi Z, Leong L, Lim D, Margolin K, Morgan RJ, Raschko J, Shibata S, Somlo G, Twardowski P, Yen Y, Doroshow JH.
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
    [Abstract] [Full Text] [Related]

  • 14. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
    Elbl L, Hrstkova H, Tomaskova I, Blazek B, Michalek J.
    Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
    [Abstract] [Full Text] [Related]

  • 15. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy].
    Wang P, Zhang S, Zhang XB, Li WJ, Hao XM, Zhang J.
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):135-9. PubMed ID: 23714670
    [Abstract] [Full Text] [Related]

  • 16. Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
    Doroshow JH.
    Curr Pharm Biotechnol; 2012 Aug; 13(10):1949-56. PubMed ID: 22352729
    [Abstract] [Full Text] [Related]

  • 17. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.
    Choi HS, Park ES, Kang HJ, Shin HY, Noh CI, Yun YS, Ahn HS, Choi JY.
    J Korean Med Sci; 2010 Sep; 25(9):1336-42. PubMed ID: 20808678
    [Abstract] [Full Text] [Related]

  • 18. Strategies for reduction of anthracycline cardiac toxicity.
    Speyer J, Wasserheit C.
    Semin Oncol; 1998 Oct; 25(5):525-37. PubMed ID: 9783592
    [Abstract] [Full Text] [Related]

  • 19. Overview and historical development of dexrazoxane.
    Hellmann K.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):48-54. PubMed ID: 9768824
    [Abstract] [Full Text] [Related]

  • 20. European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Lopez M, Vici P.
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):55-60. PubMed ID: 9768825
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.